EMAIL THIS PAGE TO A FRIEND

Journal of vascular surgery

Defining a role for contrast-enhanced ultrasound in endovascular aneurysm repair surveillance.


PMID 23490295

Abstract

Endovascular aneurysm repair (EVAR) surveillance includes duplex ultrasound, abdominal radiography, and computed tomography angiography. Contrast-enhanced ultrasound (CEUS) has emerged as an additional modality whose role remains undefined. We evaluated whether a potential role for CEUS was the elucidation of unresolved issues following standard surveillance modalities. All patients undergoing EVAR at a tertiary referral center had surveillance based on plain abdominal radiograph and duplex ultrasound, with single arterial phase computed tomography angiography reserved for abnormalities or nondiagnostic imaging. In this prospective evaluation, from April 2010 to July 2011, discordance between imaging modalities or unresolved surveillance issues prompted CEUS. Cases and imaging were discussed in a multidisciplinary setting and outcomes recorded. During the study period, 539 patients underwent EVAR surveillance, of whom 33 (6%) had CEUS for unresolved issues (median age, 79; range, 66-90; 28 male). Median follow-up after EVAR was 23 months (range, 0-132). In all cases, CEUS was able to resolve the clinical issue, resulting in secondary intervention in 10 patients (30%). The remaining patients were returned to surveillance. Within the cohort of 33 patients, the clinical issues were categorized into three groups. Group 1: Endoleak of uncertain classification (n = 27: 21 type II, four type I, two had endoleak excluded). Group 2: Significant aneurysm expansion (≥ 5 mm) without apparent endoleak (n = 4: one type II, three had endoleak excluded). Group 3: Target vessel patency following fenestrated EVAR (n = 2: patency confirmed in both). CEUS can enhance EVAR surveillance through clarification of endoleak and target vessel patency when standard imaging modalities are not diagnostic.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

295701
Sulfur hexafluoride, ≥99.75%
F6S